[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-on-chronic-liver-failure-aclf\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-on-chronic-liver-failure-aclf":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,72,96,120,142,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100638533","plasma-exchange-half-dose-and-extracorporeal-detoxification-for-aclf-100638533",false,"NCT07593638","Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF","Phoenix","Inclusion Criteria:\n\n* Written informed consent for participation in the study\n* Admission to the ICU with a diagnosis of ACLF of reversible etiology (infection, bleeding, alcohol-related, toxic, etc.)\n* Total bilirubin ≥ 12 mg\u002FdL and INR ≥ 1.5\n* On the waiting list for liver transplantation or not a candidate for transplantation but with an indication for supportive therapy\n\nExclusion Criteria:\n\n* Refusal to provide consent\n* Pregnancy\n* Expected survival \\\u003C 24 hours due to disease severity (hemodynamic instability requiring norepinephrine \\> 0.20 mcg\u002Fkg\u002Fmin and\u002For mechanical ventilation with PaO₂\u002FFiO₂ \\\u003C 150 and\u002For non-hepatic coma)\n* ACLF severity greater than CLIF-C ACLF grade 3\n* Advanced organ dysfunction: Pulmonary (GOLD stage 3 or 4) and\u002For Cardiac (NYHA functional class III or IV)\n* Advanced or metastatic oncological disease (life expectancy \\\u003C 6 months)\n* Marked frailty syndrome or secondary sarcopenia\n* Participation in another clinical trial within the previous 3 months","ALL","18 Years",{"count":19,"type":20},240,"ESTIMATED","INTERVENTIONAL",[23],"NA","Clinical trial\n\nThe goal of this clinical trial is to learn if a liver support protocol works to treat Liver failure in adults. The main questions it aims to answer are:\n\n* Does hemoadsorption plus half-dose plasma exchange provide support to liver failure patients until recovery or transplant\n* What medical problems do participants have during the technique? Researchers will compare DPMAS plus half-dose plasma exchange with conventional treatment to evaluate a gain in recovery\n\nParticipants will:\n\n* Be submitted to DPMAS plus half dose plasma exchange daily according to protocol.\n* Monitoring will be continuous in the ICU",[26],"Acute on Chronic Liver Failure (ACLF)",[28,29,30],"DPMAS","Plasma exchange","ACLF","NOT_YET_RECRUITING","2026-05-11",{"date":34,"type":35},"2026-05-18","ACTUAL",{"date":37,"type":20},"2026-07",{"date":39,"type":20},"2028-01",{"name":41,"class":42},"Unidade Local de Saude do Nordeste","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":68,"locationsCount":71},"100625992","phase-1-egen-5784-porcine-liver-with-the-metra-elc-device-100625992","NCT07429838","EGEN-5784 Porcine Liver With the Metra® ELC Device","A Phase 1, First-in-Human Safety and Proof-of-Concept Study to Evaluate EGEN-5784 Porcine Liver (Drug Product) in Combination With the Metra® Extra-Corporeal Liver Cross-Circulation Device in Participants With Acute-on-Chronic Liver Failure","Key Inclusion Criteria:\n\n* Male or female, age 18 to 70 years, inclusive\n* Not eligible for transplantation at the time of enrollment\n* Diagnosis of Grade 2 to 3 ACLF according to the European Association for the Study of Chronic Liver Failure (EASL-CLIF) definition and Chronic Liver Failure Consortium-organ failure score (CLIF-C-OF) ≥10\n* Hepatic encephalopathy Grade 1 to 3 by West Haven Criteria\n* Written consent provided by participant or LAR (if participant lacks capacity, e.g., due to hepatic encephalopathy) prior to conduct of any study procedures\n\nKey Exclusion Criteria:\n\n* Prior solid organ transplant\n* Fulminant hepatic failure without underlying liver disease\n* Non-biological artificial liver extracorporeal liver support (e.g., molecular adsorbent recirculating system) or bioartificial liver support systems within 30 days prior to EGEN-5784 liver perfusion\n* Liver dysfunction due to trauma, or extra-hepatic cholestasis\n* Any uncontrolled ongoing active infection\n* History or active human immunodeficiency virus (HIV) infection or acute hepatitis B virus (HBV)\n* Chronic HBV or active hepatitis C\n* Diagnosis of cancer requiring active ongoing treatment, e.g., chemotherapy, radiation therapy\n* Severe concomitant cardiovascular disease defined as congestive heart failure Class III and IV\n* Significant acute or chronic pulmonary disease requiring ventilator support or diagnosed with chronic obstructive pulmonary disease Global Obstructive Lung Disease \\[GOLD\\] stage III or IV disorder\n* Active uncontrolled bleeding (i.e., any major blood loss requiring ≥2 units of pRBCs within the last 48 hours prior to screening)\n* Any other health condition, including illicit drug use, that would preclude participation in the study in the judgement of the PI","70 Years",{"count":53,"type":20},20,[55],"PHASE1","This is a Phase 1, first-in-human (FIH) safety, proof-of-concept, two-part study of the genetically-engineered EGEN-5784 liver in combination with the metra® extra-corporeal liver cross-circulation (ELC) system in participants with Grade 2 to Grade 3 acute-on-chronic liver failure (ACLF) and hepatic encephalopathy Grade 1-3. The metra® device has been modified for the purposes of cross-circulation with an extra-corporeal porcine liver. The EGEN-5784 liver and metra® ELC device are designed to support liver function during the treatment period",[26,58],"Hepatic Encephalopathy (HE)",[60,61],"Extra-corporeal live cross-circulation","Metra","2026-05-05",{"date":64,"type":35},"2026-05-07",{"date":66,"type":20},"2026-06",{"date":39,"type":20},{"name":69,"class":70},"eGenesis, INC","INDUSTRY",2,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100619642","phase-3-a-novel-extracorporeal-liver-support-therapy-in-alcf-and-to-evaluate-the-efficacy-of-dialive-20-a-liver-dialysis-device-100619642","NCT07347275","A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device.","A Multi-Centre, Randomised, Controlled Trial to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device, for the Treatment of Acute-on-Chronic Liver Failure (ACLF) A-TANGO Grade 2-4 Compared to Standard of Care (SoC)","Inclusion Criteria:\n\n* Adults aged 18-70 years, with a diagnosis of ACLF grade 2-4 (according to A-TANGO ACLF criteria, APPENDIX 1)\n* ACLF non-responsive to SoC for up to 48 hours prior to developing grade 2-4 ACLF.\n* Inclusion within 10 days from the onset of A-TANGO ACLF grade ≥ 2.\n\nExclusion Criteria:\n\n* A-TANGO ACLF grade ≥2 for more than 10 days prior to inclusion\n* Pregnancy\n* Co-infection with HIV and AIDS defining illness i.e. CD4+ T-cell count below 200 cells\u002FµL, a CD4+ T-cell percentage of total lymphocytes of less than 15%, or one of the defining illnesses such as PCP, Kaposi's sarcoma, CMV, Candidiasis etc.\n* Bacterial infection or sepsis unresponsive to treatment with antimicrobials for 48 hours indicated by (a) persistent pyrexia (b) rising white cell count, creactive protein and lactate (c) persistently positive cultures for bacteria or fungi and\u002For (d) worsening clinical state indicated by escalating requirement for fluid resuscitation, increasing vasopressors requirements or increasing organ support.\n* Invasive fungal infection (clinical or radiological evidence, not solely biomarker positivity such as BDG or galactomannan)\n* Acute or sub-acute liver failure in the absence of cirrhosis\n* Post-hepatectomy liver failure or primary non-function following transplantation\n* Previous liver transplant\n* Severe thrombocytopaenia (absolute platelet count \\\u003C20,000\u002Fmm3 at screening) or evidence of rapid decline in platelet count (\\> 50% reduction within the preceding 24 hrs)\n* INR \\>3.0, unless sustained correction for \\>24 hours following FFP\u002FPCC treatment\n* Severe disseminated intravascular coagulopathy (DIC)\n* Persistent haemodynamic instability as defined by:\n\n  (i) Norepinephrine(NE) dose \\>0.5µg\u002Fkg\u002Fmin, or, (ii) If a second pressor is used, a composite Norepinephrine equivalence index (NEEI) of dose \\>0.5µg\u002Fkg\u002Fmin (iii) Arterial lactate level \\>4mmol\u002FL despite 24 hours of adequate fluid resuscitation and pressor therapy\n* Severe respiratory failure: PaO2\u002FFiO2 (P\u002FF) ≤ 200 mmHg or 27kPa\n* Established on renal replacement therapy for longer than 24 hours prior to inclusion\n* A-TANGO WCC ACLF score \\>64 (APPENDIX 1)\n* Significant and\u002For uncontrolled bleeding (participants can be enrolled 48 hours after bleeding is controlled)\n* Active or prior history of non hepatic malignancy unless adequately treated or in complete remission for five or more years\n* HCC outside of Milan criteria.\n* Acute, extensive, portal vein thrombosis extending to and occluding superior mesenteric vein\n* Major systemic illness, aside from liver disease, that in the opinion of the investigator would preclude the participant from participating in the study (e.g. coronary artery disease, cerebrovascular disease, chronic pulmonary disease, chronic kidney disease, serious psychiatric disease)\n* Pre-existing chronic kidney disease (CKD) defined as eGFR (estimated glomerular filtration rate) \\\u003C30 mL\u002Fmin for 3 months or longer prior to screening\n* Severe frailty (Clinical Frailty Scale, CFS\\>5)\n* Severe malnourishment (BMI\\\u003C18)\n* Participants not considered appropriate for full active treatment including organ support\n* Participants who have a \"do not attempt cardio-pulmonary resuscitation\" order in place\n* Any participant who has received an investigational drug or device within 30 days, or who is scheduled to receive another investigational drug or device during the course of the study (concomitant observational studies are allowed)\n* Uncontrolled seizures\n* Evidence of new intracranial pathology such as cerebral hemorrhage or infarction.\n* Participants diagnosed with Creutzfeldt-Jakob disease.\n* Participants unable to consent for themselves, unless a legal representative\u002Fconsultee is appointed and approved as dictated by local and national legislation.\n* Known allergy to heparin, or type II thrombocytopaenia caused by heparin (HIT syndrome type II).\n* In the opinion of the investigator, recruitment to the the study would be unsafe for the participant.",{"count":80,"type":20},72,[82],"PHASE3","This study is intended to demonstrate the efficacy and safety of the DIALIVE Liver Dialysis Device when incorporated into the standard management plan for participants with A-TANGO ACLF grade 2-4.\n\nA total of 72 evaluable participants, aged 18-70, will be enrolled in up to 12 clinical centres in the United Kingdom. Participants must have a history of liver cirrhosis and a deterioration within four weeks due to a precipitating event, leading to A-TANGO ACLF grade 2-4. Multicenter, individually randomised, controlled, open-label, parallel group trial using double-arm design. The control group will receive SoC for participants with ACLF. The DIALIVE 2.0 treatment group will receive SoC with the addition of up to 7 (seven) daily DIALIVE 2.0 treatment sessions within the 10-day treatment window. Seventy-two participants with ACLF (60% A-TANGO ACLF grade 2 at randomisation, and 40% A-TANGO ACLF grade 3 \\& 4 at randomisation) will be randomised 1:1 to receive either SoC or SoC + DIALIVE 2.0. This allows for 5% loss due to drop-out, and 5% censoring due to liver transplantation within 28 days. All randomised participants will be included in the intention to treat (ITT) analysis while all participants that receive at least one treatment cycle will be used for the safety population. For each participant, the study duration will be up to 105 days (screening: 5 days; treatment up to 10 days; follow up 90 days).\n\nThe total study duration is estimated to be approximately 18 months from screening of first participant until study completion of the last participant.",[85,86],"Acute-on-Chronic Liver Failure (ACLF)","Liver Cirrhosis","2026-04-08",{"date":89,"type":35},"2026-04-14",{"date":91,"type":20},"2026-05",{"date":93,"type":20},"2027-05",{"name":95,"class":70},"Yaqrit Ltd",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100607154","vitamin-c-for-acute-kidney-injury-in-aclf-with-septic-shock-a-randomized-controlled-trial-100607154","NCT07184866","Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial","A Randomized Controlled Trial Open Label Evaluating the Efficacy of Vitamin C in Improving Outcomes of Acute Kidney Injury in Patients With ACLF With Septic Shock","VITAKI-ACLF","Inclusion Criteria:\n\n* ACLF as per asia pacific association for the study of liver (APASL criteria) with AKI according to KDIGO Criteria and septic shock.\n\nExclusion Criteria:\n\n* • Refractory Septic shock with more than 3 organ failures.\n\n  * Patients with age less than 18 years\n  * Known severe cardiopulmonary disease (structural or valvular heart disease, coronary artery disease, COPD)\n  * Patients in DIC with platelets \\\u003C 20,000 and INR \\> 4 or active bleeding\n  * Limitations of care (defined as refusal of cardiovascular and respiratory support modes) including \"do not intubate\" (DNI) status\n  * Current hospitalization \\> 15 days for patients with nosocomial acquisition of MDR at time of randomization\n  * Known allergy or contraindication to vitamin C (including previously or currently diagnosed primary hyperoxaluria and\u002For oxalate nephropathy, or known\u002Fsuspected ethylene glycol ingestion,\n  * Known glucose-6-phosphate dehydrogenase (G6PD) deficiency)\n  * Use of vitamin C at a dose of \\> 1 gram daily within the 24 hours preceding first episode of qualifying organ dysfunction during a given ED or ICU admission\n  * Patients with HCC (beyond Milan) or extrahepatic malignancies\n  * Patients with HVOTO or EHPVO\n  * Pregnancy or active breastfeeding\n  * Current participation in another interventional research study\n  * Active or history of kidney stones\n  * History of chronic kidney disease or intrinsic kidney disease\n  * Patients already on maintenance hemodialysis prior to presentation\n  * Failure to provide informed consent\n  * Patients with retroviral infection\n  * Patients with active hemolysis due to alcohol or other causes or with hemoglobin below 7 gm\u002Fdl",{"count":105,"type":20},110,[23],"This study is testing whether Vitamin C can help improve kidney function and survival in very sick patients with liver disease. Patients with acute-on-chronic liver failure (ACLF) often develop serious infections that can lead to septic shock and kidney injury, which are major causes of death.\n\nIn this randomized controlled trial, patients with ACLF and septic shock will be assigned to receive either:\n\n1. Standard medical treatment alone, or\n2. Standard medical treatment plus intravenous Vitamin C.\n\nVitamin C is a safe, inexpensive antioxidant that may reduce inflammation, improve circulation, and protect the kidneys. The study will compare how well patients recover from septic shock and kidney injury in the two groups. Blood and urine samples will also be collected to look for biological markers that can predict outcomes.",[85],[110],"Sepsis, septic shock, Alcohol-related, ACLF, AKI, Lactate, Vitamin","2026-03-24",{"date":113,"type":35},"2026-03-25",{"date":115,"type":20},"2026-04",{"date":117,"type":20},"2027-10",{"name":119,"class":42},"Institute of Liver and Biliary Sciences, India",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":141,"locationsCount":4},"100606654","double-plasma-separation-and-adsorption-in-acute-on-chronic-liver-failure-dpmas-aclf-trial-100606654","NCT07178366","Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)","Impact of Double Plasma Separation and Adsorption on Patients With Acute on Chronic Liver Failure- A Prospective Open-label Randomized Controlled Trial","DPMAS-ACLF","Inclusion Criteria:\n\n* ACLF patients of any etiology with systemic inflammatory response syndrome and AARC grade II or more.\n\nExclusion Criteria:\n\n* Patients eligible for corticosteroids for severe alcohol-associated hepatitis related ACLF (other than hydrocortisone according to Surviving Sepsis Campaign Guidelines 2021 which is 50 mg iv q 6 h for management of refractory shock\n* Hepatocellular carcinoma or any extrahepatic malignancy,\n* Active fungal sepsis\n* Disseminated intravascular coagulation\n* Hemodynamic instability requiring norepinephrine \\>0.20ug\u002Fkg\u002Fmin\n* Patients with coma of non-hepatic origin\n* Patients with PaO2\u002FFiO2 ratio \\\u003C150\n* Pregnancy\n* Comorbidities associated with poor outcomes (severe cardiopulmonary disease defined by a New York Heart Association score \\>3, or oxygen\u002Fsteroid-dependent chronic obstructive pulmonary disease, chronic kidney disease) and patients with post-resection liver failure\n* Patients with fibrinogen \\\u003C110 and\u002For platelets less than 50,000\n* Patients with oliguria with urine output less than 400 ml\u002Fday\n* Lack of informed consent\n* Patient enrolled in other clinical trials",{"count":129,"type":20},56,[23],"Acute-on-chronic liver failure (ACLF) is a serious condition in which patients with chronic liver disease suddenly develop severe liver injury, leading to inflammation, organ failure, and very high short-term mortality. Standard medical treatment can help, but many patients still do poorly without liver transplantation.\n\nThis study will test whether Double Plasma Molecular Adsorption System (DPMAS), an extracorporeal blood purification therapy, can improve outcomes in ACLF patients. DPMAS works by filtering the blood through special adsorption columns that remove harmful substances such as bile acids, toxins, and inflammatory molecules.\n\nIn this randomized controlled trial, adult patients with ACLF will be randomly assigned to receive either:\n\nStandard medical therapy alone, or\n\nStandard medical therapy plus DPMAS.\n\nThe main goal is to see whether DPMAS can improve liver function and reduce disease severity within 14 days. Other outcomes include survival without liver transplant at 28 days, improvement in organ functions, reduction in inflammation, and safety of the procedure.\n\nThe study will be conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, India, and will enroll about 56 participants over one year.",[85],[30,28,134,135,136],"Lactate","Sepsis","Liver support",{"date":113,"type":35},{"date":139,"type":20},"2026-05-10",{"date":117,"type":20},{"name":119,"class":42},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100508033","phase-2-a-novel-combinatorial-therapy-with-albumin-and-enoxaparin-in-patients-with-decompensated-cirrhosis-at-high-risk-of-poor-outcome-combat-trial-100508033","NCT05895136","A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).","COMBAT","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Patients with decompensated cirrhosis admitted to hospital due to AD according to the EASL-CLIF criteria (rapid onset of ascites, hepatic encephalopathy, portal hypertensive-related gastrointestinal bleeding, bacterial infection, or any combination of these).\n3. CLIF-C AD score ≥ 45 at admission or at any time during hospital stay.\n4. Recovery from AD and expected to be discharged within the next 72 hours.\n\nExclusion Criteria:\n\n1. Diagnosis of acute-on-chronic liver failure (ACLF) grade 3 or higher according to the EASL-CLIF criteria at admission or at any time during the index hospitalization\n2. Admission for planned diagnostic or therapeutic procedures\n3. Recent acute bleeding (unless the cause has been effectively treated and there is no evidence of ongoing bleeding for at least 5 days)\n4. Chronic bleeding requiring periodic blood transfusions\n5. Presence of an ongoing acute complication of the disease (i.e. hepatic encephalopathy \\[grade III or IV\\])\n6. Conditions with a high risk of haemorrhage, including haemorrhagic diathesis not related to liver disease\n7. Patients with INR \\> 3.0\n8. Severe thrombocytopenia (\\\u003C30x10 9 \u002FL)\n9. Ongoing chronic anticoagulation therapy or indication for starting anticoagulation due to hepatic and non-hepatic conditions\n10. Ongoing anti-platelets therapy.\n11. Active malignancy (except for hepatocellular carcinoma within the Milan criteria or non-melanocytic skin cancer)\n12. Antiviral treatment for hepatitis C, B and delta initiated in the last 6 months or planned to be initiated in the following 6 months\n13. Ongoing alcohol use disorder with an expected low adherence to protocol as judged by physician\n14. Previous liver transplantation\n15. Patients with TIPS or other surgical porto-caval shunts\n16. Chronic organic renal failure stage IV and V or estimated Glomerular Filtration Rate \\\u003C30 ml\u002Fmin according to the MDRD equations\n17. Chronic heart failure NYHA class III or IV\n18. Pulmonary disease GOLD III or IV\n19. Patients with extrahepatic diseases with life expectancy \\\u003C6 months\n20. Severe psychiatric disorders\n21. Hypersensitivity to albumin preparations or to any of the excipients.\n22. Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins (LMWH) or to any of the excipients\n23. History of immune mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies\n24. Pregnancy and breast-feeding\n25. Expected low adherence to study protocol as judged by physician\n26. Patients who can't provide written informed consent or refusal to participate\n27. Participation in other concurrent clinical trials and within the prior 3 months from informed consent signature.","80 Years",{"count":151,"type":20},90,[153],"PHASE2","The goal of this clinical trial is to determine primarily whether a combinatorial therapy based on the administration of human albumin and enoxaparin is safe and effective in patients with decompensated cirrhosis discharged from the hospital. The main questions it aims to answer are:\n\n* Is this combinatorial therapy safe and tolerable?\n* Is this combinatorial therapy effective?\n* does this combinatorial therapy cost more or less than standard medical therapy? Participants will attend to study visits in which several test will be performed to asses disease evolution while they are taking study medication.\n\nResearchers will compare experimental group treated with combinatorial therapy plus standard treatment with control group treated with standard treatment to see if there are differences in the responses to the questions raised above.",[86,156,26],"Decompensated Cirrhosis of Liver",[158,26,159,160,161,162],"decompensated cirrhosis","Liver diseases","liver cirrhosis","Human Albumin","Enoxaparin","RECRUITING","2025-03-14",{"date":166,"type":35},"2025-03-19",{"date":168,"type":35},"2024-07-01",{"date":170,"type":20},"2025-09",{"name":172,"class":42},"European Foundation for Study of Chronic Liver Failure",9,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":184,"studyType":185,"phases":4,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100580474","study-about-hepatic-toxins-kinetic-and-evaluation-of-organ-damage-in-acute-on-chronic-liver-failure-aclf-patients-100580474","NCT06837766","Study About Hepatic Toxins Kinetic and Evaluation of Organ Damage in Acute on Chronic Liver Failure (ACLF) Patients","Observational Study About Hepatic Toxins Kinetic and Evaluation of Organ Damage in Acute on Chronic Liver Failure (ACLF) Patients: Multicenter Prospective Observational Spontaneous Study","BILIVER2020","Inclusion Criteria:\n\n* diagnosis of acute hepatic decompensation on chronic liver disease with grade ACLF ≥ 2 (diagnosable in the presence of at least two defined organ failures according to the CLIF-C-OF score);\n* hemoabsorbent treatment with Cytosorb;\n* patients aged ≥ 18 years at the time of diagnosis;\n* Informed Consent.\n\nExclusion Criteria\n\n* patients aged \\\u003C 18 years;\n* fulminant liver failure;\n* chronic end-stage liver failure with chronic encephalopathy and\u002For chronic refractory ascites;\n* acute on chronic hepatic decompensation with grade 0 or 1 ACLF;\n* clinical signs or history of congestive heart failure (NYHA class 3-4 before the acute phase of the disease or documented EF \\\u003C 35% or PCWP \\> 18 mmHg) or acute coronary syndrome\n* state of immunosuppression (rheumatological and immunological diseases, HIV, immunosuppressive therapy);\n* previous organ transplant.",{"count":183,"type":20},40,"28 Days","OBSERVATIONAL","Spontaneous Observational Prospective Multicenter study of all patients admitted to Intensive Care with a diagnosis of Acute on Chronic Liver Failure (ACLF) of grade ≥ 2 for which the use of the system will be authorized extracorporeal purification with DM CYTOSORB. The hypothesis underlying the study is to evaluate whether the modulation of bilirubin and other toxic molecules and mediators, obtainable through the use of systems extracorporeal purification (specifically DM CYTOSORB), may have an impacton the degree of organ failure in patients with ACLF.\n\nThe study proposes the compilation of a structured and shared data collection with other Italian Intensive Care Centers which include patients suffering from ACLF (multicenter study) of clinical and laboratory parameters, which are part of normal clinical practice.",[26],[189,190,191,192],"Acute on Chronic Liver Failure (ACLF),","Model for End stage Liver Disease (MELD)","Chronic LIver Failure - Consortium Organ Failure (CLIF-C OF)","Renal Replacement Therapy (RRT)","2025-02-19",{"date":195,"type":35},"2025-02-20",{"date":197,"type":35},"2021-09-29",{"date":199,"type":20},"2025-12-31",{"name":201,"class":42},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",3]